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Abstract
The pathogenesis of liver cirrhosis is not completely 
elucidated. Although in the majority of patients, the risk 
factors may be identified in B and C viral hepatitis, alco-
hol intake, drugs or fatty liver disease, there is a small 
percentage of patients with no apparent risk factors. In 
addition, the evolution of chronic liver disease is highly 
heterogeneous from one patient to another. Among 
patient with identical risk factors, some rapidly prog-
ress to cirrhosis and hepatocellular carcinoma (HCC) 
whereas others have a benign course. Therefore, a ge-
netic predisposition may contribute to the development 
of cirrhosis and HCC. Evidence supporting the role of 
genetic factors as a risk for cirrhosis has been accumu-
lating during the past years. In addition to the results 
from epidemiological studies, polymorphisms studies 
and data on twins, the concept of telomere shorten-
ing as a genetic risk factor for chronic liver disease and 
HCC has been proposed. Here we review the literature 
on telomerase mutations, telomere shortening and liver 
disease including hepatocellular carcinoma.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Liver-cirrhosis; Hepatocarcinoma 
Core tip: The pathogenesis of liver cirrhosis is not com-
pletely elucidated. Genetic predisposition may contrib-
ute to the development of cirrhosis and hepatocellular 
carcinoma (HCC). Evidence supporting the role of ge-
netic factors as a risk for cirrhosis and the concept of 
telomere shortening as a genetic risk factor for chronic 
liver disease and HCC has been proposed. Here we re-
view the literature on telomerase mutations, telomere 
shortening and liver disease including hepatocellular 
carcinoma.
Carulli L, Anzivino C. Telomere and telomerase in chronic liver 
disease and hepatocarcinoma. World J Gastroenterol 2014; 
20(20): 6287-6292  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v20/i20/6287.htm  DOI: http://dx.doi.
org/10.3748/wjg.v20.i20.6287
TELOMERE AND TELOMERASE
Telomeres consist of  repetitive DNA sequences (TTAGGG) 
associated with a specialized protein complex named 
shelterin and are located at the ends of  linear chromo-
somes. They function as a cap to stabilize and protect 
chromosomes from erosion and from being mistaken for 
double-strand DNA breaks[1]. During each cell division, 
telomeres shorten due to the ‘‘end-replication problem’’ 
that is the DNA polymerase’s inability to fully replicate 
the 3’ end of  chromosomes. In order to limit telomere at-
trition, germline and some somatic cells express telomer-
ase, a reverse transcriptase that maintains telomere length 
by synthesizing new DNA sequences and adding them to 
the end of  the chromosome[2]. Telomerase is an enzymat-
ic protein complex including the telomerase reverse tran-
scriptase (TERT) and the telomerase RNA component 
(TERC) used as a template to synthesize telomere DNA.
When telomeres are too short, they signal the arrest 
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of  cell proliferation resulting in cell senescence or apop-
tosis. If  protective mechanisms, such as the p53 tumor-
suppressor gene, are inactive, thus allowing continued 
proliferation, telomeres become extremely short and dys-
functional; they may cause chromosomes end-to-end fu-
sions and ultimately chromosomal instability. Conversely, 
cells transfected with the telomerase gene can prolifer-
ate indefinitely[3]. Despite telomerase activity, telomere 
shortening is inevitable, thereby limiting the proliferative 
lifespan of  human cells. As expected, for a given organ, 
telomere length decreases with the age of  the subjects. 
There are also iatrogenic causes of  telomere shortening: 
for example after bone marrow transplantation when 
hematopoietic stem cells and progenitor cells are highly 
proliferative in order to reconstitute hematopoiesis. In 
addition, telomere attrition may be genetically determined 
as a result of  telomerase complex’s genes mutations lead-
ing to an inherited inability to elongate telomeres.
TELOMERE AND DISEASE
Mutations in the TERT and TERC genes are considered 
the most common cause of  inherited human telomere-
mediated disease[4]. Even with a mild reduction in telom-
erase activity, telomere length homeostasis may be altered 
and results in what has been called a syndrome complex 
which include different age-dependent disease[5,6]. Telo-
mere-mediated disease has diverse presentations that span 
the age spectrum. Their type, age of  onset, and severity 
depend on the extent of  the telomere length defect (Table 
1). Telomerase mutations may have high penetrance and 
induce, during infancy, severe telomere shortening that 
manifests as developmental delay, cerebellar hypoplasia, 
and immunodeficiency, features that are recognized in the 
rare Hoyeraal-Hreidarsson syndrome[7,8].
In children and young adults, telomere-mediated 
disease causes bone marrow failure and at times may be 
recognized in the mucocutaneous syndrome dyskeratosis 
congenita, which is defined by a triad of  mucocutaneous 
features: skin hyperpigmentation, dystrophic nails, and 
oral leukoplakia[9-11]. During adult life, telomerase muta-
tions may represent risk factors rather than genetic de-
terminants and need environmental, epigenetic or other 
genetic factors to contribute to disease development. 
These mutations are less penetrant and induce single-or-
gan damage in adults, usually without the classic physical 
signs of  dyskeratosis congenita. This is case of  diseases 
such as aplastic anemia, pulmonary fibrosis and liver cir-
rhosis. Telomere-mediated disease manifests in adults as 
isolated or syndromic clustering of  idiopathic pulmonary 
fibrosis (IPF), liver cirrhosis, and bone marrow failure[12]. 
Mutant TERT and TERC genes account for 8%-15% 
of  familial and 1%-3% of  sporadic pulmonary fibrosis 
cases[13-15]. The co-occurrence of  IPF and bone mar-
row failure within a single family is highly predictive for 
the presence of  a germline telomerase defect[16]. Mutant 
telomere genes do not cause only isolated cases of  IPF, 
liver cirrhosis or aplastic anemia but they may also cause 
subclinical diseases in other organs even if  one single or-
gan disease manifestations dominate. For example patient 
with IPF who have a telomerase mutation is at increased 
risk to develop liver diseases as well as bone marrow 
failure[13,14]. It has been proposed that their shared short 
telomere length defect unifies them as a single syndrome 
continuum[17] (Table 2). This classification is significant 
because the telomere defect is present in the germline of  
these patients and thus, even when a single presentation 
predominates, complications may arise in other organs. 
The consideration of  the telomere syndromes as a single 
spectrum is important for patient management in differ-
ent clinical settings. 
TELOMERE AND LIVER DISEASE
The pathogenesis of  liver cirrhosis is not completely 
elucidated. Although in the majority of  patients a cause 
can be identified in viral hepatitis, alcohol intake, drugs 
or fatty liver disease, there is still a small percentage of  
patients with no apparent risk factors[18]. In addition, it is 
not either completely elucidated why patients with identi-
cal risk factors have a different clinical manifestations and 
clinical course; in fact some patients progress to cirrhosis 
and/or hepatocellular carcinoma (HCC) whereas others 
have a benign clinical course, suggesting that host factors, 
different from age and gender, may play a critical role in 
disease progression. Many attempts to identify possible 
genetic risk factors for the development of  cirrhosis have 
been done with little fortune. Among others, the concept 
of  telomere shortening as genetic risk factor for cirrhosis 
has been proposed. Conditions with high cell turnover 
such as chronic liver injury accelerate telomere shorten-
ing, leading to impairment of  cell proliferation and se-
nescence once telomeres are critically short. The cellular 
growth arrest and/or senescence appears to be profibro-
genic by as-yet undefined mechanisms. Several studies 
have investigated the relationship between cirrhosis and 
telomere shortening, showing that telomeres shortening 
is a marker of  cirrhosis formation correlating with the 
accumulation of  senescent hepatocytes[19]. Kitada et al[20] 
demonstrated the relationship between telomere shorten-
ing and cirrhosis in 1995. They observed that telomere 
Carulli L et al . Telomere and liver disease
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Table 1  Telomere erosion and human disease
Telomerase mutations as 
genetic determinants
Telomerase mutations as 
genetic risk factors
Characteristics High penetrance Low penetrance 
Childhood onset disease Adult onset disease 
Congenital clinical 
manifestations
Single or multiple organs
Disease Dyskeratosis congenita Aplastic anemia
Lung fibrosis
Liver cirrhosis 
Telomere syndromes
Telomerase mutations may be highly penetrant causing congenital clinical 
manifestations as in dyskeratosis congenita or may be less penetrant and 
manifest in adult life inducing single or multiple organ damage[7]. 
length in tissue from cirrhotic liver was shorter than in 
liver with chronic hepatitis and both were shorter than 
telomere length in normal liver tissue. Subsequent studies 
confirmed that a shortened telomere length was corre-
lated with the degree of  fibrosis, suggesting that telo-
mere shortening may contribute to and be a marker of  
cirrhosis[20-22]. Moreover, studies on telomerase-deficient 
mice provided experimental evidence that shortened telo-
meres, in response to chronic liver injury, are associated 
with impaired liver regeneration and accelerated cirrhosis 
development. Restoration of  telomerase activity into the 
liver of  these mice resulted in reduction of  cirrhosis and 
improved liver function[23]. These findings suggest that 
reduced telomerase activity may contribute to cirrhosis 
development. 
Mutations in the telomerase complex genes have 
been implicated in rare human diseases characterized by 
accelerated telomere shortening and organ failure such 
as dyskeratosis congenita[7]. Interestingly, patients suffer-
ing from these diseases showed an increased frequency 
of  liver pathologies including fibrosis and cirrhosis. 
Our group was the first to report on the coexistence of  
cryptogenic cirrhosis (CC) and IPF, not in the setting 
of  dyskeratosis congenita, and telomere disfunction. 
We described a case report on 48-year-old woman, diag-
nosed of  cryptogenic liver cirrhosis, idiopathic pulmo-
nary fibrosis and diabetes. Both CC and IPF had a rapid 
progression and after eighteen months the patient died. 
Sequencing and mutation analysis of  TERT and TERC 
genes demonstrated the presence of  a heterozygous 
TERT mutation (L153M). The TERT L153M variant re-
sults in a change of  methionine for leucine at amino acid 
153, in the protein region that seems to be involved in 
the template RNA and telomeric DNA binding. Further-
more, leukocyte telomere length was significantly shorter. 
Our case report not only confirmed the association 
between IPF and telomere dysfunction, but, more inter-
estingly, gives further evidence of  telomere involvement 
in liver disease progression and suggests a possible link 
between nonalcoholic fatty liver disease (NAFLD) and 
CC through telomere shortening[24,25]. Recently, two stud-
ies have also investigated the frequency of  telomerase 
mutations in patients with sporadic cirrhosis compared 
to healthy controls[26,27]. Both studies screened patients 
for variation in the TERT and TERC genes. In the first 
study by Calado et al[26] the Authors found missense mu-
tations in the TERT and TERC genes. The frequency of  
TERT gene mutations in cirrhotic patients was signifi-
cantly greater than controls. Moreover cirrhosis was also 
associated with shorter telomeres in peripheral blood 
leukocytes. Finally, most TERT variants showed reduced 
telomerase activity in vitro. In the second study Hartmann 
et al[27] screened patients with sporadic cirrhosis and non-
cirrhotic controls for telomerase mutations. Of  note, 
control group was composed of  473 healthy individuals 
and 127 patients with chronic HCV infection who did 
not develop cirrhosis during a long follow-up. The data 
analysis revealed a significantly increased frequency of  
telomerase mutations in the cirrhosis group compared to 
the control group. Again, TERT gene mutations in cir-
rhotic patients were associated with reduced telomerase 
activity in vitro and shorter telomeres in peripheral blood 
leukocytes compared to non-cirrhotic patients. Interest-
ingly, Hartmann et al[27] found an increased frequency of  
end stage liver disease (Child B or C cirrhosis, hepatocel-
lular carcinoma, or evaluation for liver transplantation) 
in cirrhotic patients harboring telomerase mutations 
compared to cirrhotic patients without telomerase muta-
tion. This result suggests that telomerase mutations may 
accelerate liver disease progression to cirrhosis in a con-
text of  chronic liver injury. Telomerase mutations were 
very different between the two studies; the most com-
mon TERT variant in the Calado study (A1062 T found 
in six patients) was not found in the Hartmann study and 
conversely, the most common TERT variant in the Hart-
mann study (G1109R also found in six patients) was not 
found in the study by Calado. Together, the current data 
would suggest that telomere attrition may play a role in 
the sequence of  events leading to cirrhosis. According to 
this view chronic liver injury induces hepatocyte regen-
eration and therefore an elevated cell turnover; hence in-
creased telomere shortening and cell senescence. Eventu-
ally, if  the injury persists, other cells, such as stellate cells 
become activated leading to fibrogenesis (Figure 1).
On the same line, however, a recent study[28], conduct-
ed on liver sections from 70 patients with NAFLD and 
60 controls, found that telomere shortening was observed 
in NAFLD patients but other indices of  cell ageing, such 
as cell cycle inhibitor p21 and nuclear area were better 
predictors of  disease progression. In fact a higher he-
patocyte p21 expression and a greater nuclear area were 
significantly associated with adverse liver-related outcome 
but not with the telomere length. Similarly, in paired 
biopsies p21 expression and nuclear area correlated to 
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Table 2  Telomere syndromes
Spectrum of features in bone marrow, lung and liver disease
Haematologic 
   Macrocytosis 
   Isolated cytopenias
   Plastic anemias
   Myelodysplasia
   Acute myeloid leukemia
Pulmonary
   Asymptomatic restrictive defects on lung function tests
   Idiopathic pulmonary fibrosis 
   Nonspecific interstitial pneumonia 
   Idiopathic interstitial pneumonias 
Liver 
   Mildly elevated transaminases
   Atrophic nodular liver at imaging studies 
   Splenomegaly
   Cryptogenic liver fibrosis/cirrhosis
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Mutant telomere genes and telomere shortening do not cause only a single 
organ damage such as idiopathic pulmonary fibrosis (IPF), aplastic anemia 
or liver cirrhosis but often the affected patient has also subclinical disease 
concurrently in other organs even if the symptoms of a single organ 
predominate[17].
TELOMERE AND HEPATOCELLULAR 
CARCINOMA
Natural history of  cirrhosis is often complicated with 
the occurrence of  hepatocellular carcinoma (HCC). The 
observation that telomere shortening is an established 
feature of  chronic liver disease has led to suggest that 
it may play a role in the pathophysiology of  HCC. This 
view stems from a large number of  studies indicating that 
telomere biology is involved in the initiation as well as in 
the progression of  HCC[31]. The telomere hypothesis of  
cancer holds that telomere shortening results in chromo-
somal instability (CIS) which drives cancer initiation. In 
this regard Plentz et al[32] analyzed specimen of  a group 
of  HCC and regenerative nodules correlating hepatocyte 
telomere length with the ploidy grade, taken as a measure 
of  chromosomal instability. These Authors showed that 
telomeres were shorter in HCC hepatocyte as compared 
to those in regenerative nodules and normal liver tissue 
and that, within group of  HCC, hepatocyte telomere 
length of  aneuploid was shorter than that of  diploid tu-
mors. Farazi et al[33] in order to better elucidate the role of  
telomere dysfunction in the development of  HCC used 
some experimental models of  HCC utilizing telomerase 
deficient mice, null for the telomerase RNA component, 
mTERC(-/-). In all HCC models both incidence and 
HCC lesions were suppressed showing on the histologi-
cal level a significant increase of  early stage neoplastic 
lesions and a reciprocal reduction of  high grade malig-
nancies. These experimental data indicate that telomere 
dysfunction plays an opposite role in the initiation versus 
the progression of  HCC.
On the other hand progression of  neoplastic growth 
needs an efficient telomere signaling. Initial studies[21] 
reported a slight increase of  telomere length in poorly 
differentiated as compared to better differentiated HCC, 
suggesting a reactivation of  telomerase and restored 
chromosomal stability to a level compatible with tumor 
cell viability. In this regard several reports have shown 
that telomerase activity was detected in nearly 90% of  
HCC as compared to only 21% of  non-tumor tissue and 
was paralleled by the increase of  TERT mRNA levels 
implying the possibility that TERT mRNA expression 
could predict or be a marker of  HCC[34-37]. The effec-
tive role of  the intact telomere/telomerase system has 
been illustrated in experimental HCC models utilizing 
telomerase knock-out mice mTERC(-/-) and littermates 
mTERC(+/-). This study has shown that being the prev-
alence of  short telomere comparable in the liver of  the 
two cohorts, the formation of  HCC was strongly sup-
pressed in mTERC(-/-) as compared to mTERC(+/-)[38]. 
Mechanism of  telomerase activation may be diverse in 
some way depending on the etiology of  chronic liver dis-
eases[39]. This is best illustrated by the occurrence of  the 
integration of  hepatitis B virus into the human telom-
erase gene in HCC[40,41]. Moreover the list of  recurrent 
fibrosis stage. 
Taken together these data show the relation between 
telomerase mutation and chronic liver disease progression 
to cirrhosis, probably due to a reduced telomerase activity 
and therefore an impaired telomere length maintenance. 
Moreover, since the prevalence of  telomerase mutations 
seems to be to be rather low in the general population, 
they may not be the major contributing factor to cirrho-
sis. Probably looking for telomerase genes mutations only, 
there is the risk to underestimate the real contribution 
of  the telomere system to the development of  cirrhosis. 
In fact other components of  the telomere complex have 
been shown to be important for telomerase activity, these 
components are proteins such as dyskerin and the telo-
mere binding proteins[29]; mutations in these components 
can lead to an impairment of  telomere function; recently 
a mutation of  the binding protein TIN2 has been in-
volved in the evolution of  aplastic anemia[30]. Finally 
also the mutations in the noncoding sequence of  TERC 
and TERC could be responsible for impairment in the 
expression of  TERC and TERT. Probably the sequence 
analysis of  all components of  the “telomere system” will 
reveal the real contribution of  telomere complex genes 
mutations to the development of  liver cirrhosis.
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Injury
Cell death
Regeneration
High cell turnover 
and telomere 
shortening
Telomerase mutations 
and reduced telomerase 
activity
Critically short telomere
Exhausted regeneration
Fibrosis
Figure 1  Telomere shortening and liver disease: A possible mechanism. 
Injuries leading to cell death cause repair and regeneration process which in 
turn leads to increased cell turnover and therefore to telomere erosion. If a 
telomerase gene mutation is present, telomerase activity may be reduced and 
telomere may become critically short leading hepatocyte to senescence. Hepa-
tocyte senescence is a profibrotic state that activates stellate cells responsible 
for fibrosis[25].
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HBV target genes is expanding[42] suggesting the possible 
mechanisms by which HBV may cause telomere dysfunc-
tion leading to initiation as well progression of  HCC[43-47]. 
In conclusion our knowledge of  the causes and mecha-
nisms relating telomere dysfunction to the genesis and 
growth of  HCC is increasing and leads to foresee thera-
peutic approaches, such as combined immune-chemo-
therapy and gene therapy, for its cure[48,49].
CONCLUSION
Telomere shortening and telomerase regulation play 
an important role on tissue regeneration during aging, 
chronic diseases and on cancer promotion and progres-
sion. In chronic liver disease the hepatocytes regenerative 
capacity is limited by telomere shortening, resulting in 
exhaustion of  cell regeneration, fibrosis and cirrhosis for-
mation. Short telomeres increase the risk of  HCC but at 
the same time they limit the progression of  cancer. The 
therapeutic option of  blocking senescence, reactivating 
the telomerase, in order to block the exhaustion of  the 
liver regenerative capacity might be beneficial depending 
on the effect of  such approach on the HCC formation. 
Further studies are needed in order to better understand 
telomere biology in human disease and carcinogenesis 
and to identify potential therapeutic options.
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